Studies: Spending on Accelerated Approval Drugs Is Growing Fast

The FDA’s accelerated approval pathway for experimental therapies has been criticized by practitioners and health insurers in recent months following the controversial approval of Alzheimer’s drug Aduhelm (aducanumab). Aduhelm is just the latest of many experimental therapies that has been approved with limited clinical evidence of efficacy — and payers and independent researchers say the FDA should revamp the process to contain costs.

© 2022 MMIT

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured_AdobeStock_414656276_Editorial_Use_Only.jpg
January 13

In Blow to PBMs, CMS Floats Reform of Part D Price Concessions

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured_AdobeStock_68809113.jpg
January 13

PBMs Will Face Pressure From Transparency Rules, Startups

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured-Image_Reality-Check_Breast-Cancer.jpg
January 13

Payer Groups Applaud CMS Coverage Decision on Aduhelm

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today